Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III
Standard
Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III. / Kuhn, W; Jänicke, F; Pache, L; Hölscher, M; Schattenmann, G; Schmalfeldt, B; Anderl, H; Schüle, G; Dettmar, P; Siewert, J R.
In: GEBURTSH FRAUENHEILK, Vol. 53, No. 5, 05.1993, p. 293-302.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III
AU - Kuhn, W
AU - Jänicke, F
AU - Pache, L
AU - Hölscher, M
AU - Schattenmann, G
AU - Schmalfeldt, B
AU - Anderl, H
AU - Schüle, G
AU - Dettmar, P
AU - Siewert, J R
PY - 1993/5
Y1 - 1993/5
N2 - From 1982 to 1992 103 patients with ovarian cancer stage FIGO III have been treated. In 38% of the patients there was no residual tumour postoperatively, in 40.8% the residual tumour was smaller than 2 cm. In 51.5% bowel resections were necessary, a stoma was unavoidable in just one case. A lymphadenectomy (pelvic, paraaortic or combined) was done in 46.6% of the patients. Postoperatively, 54.4% of the patients received a platinum-based chemotherapy, in the other patients other kinds of chemotherapy were applied. A radiation of the whole abdomen was done only in 3.9%. A median survival time for more than 60 months could be achieved in tumour-free patients due to the increased radical operations in combination with the platinum based chemotherapy. The lymphadenectomy seems to prolong the survival time of the patients. The positive nodal status is definitely unfavourable for the prognosis. By this therapeutic approach, an increased survival time with a good life quality can be achieved.
AB - From 1982 to 1992 103 patients with ovarian cancer stage FIGO III have been treated. In 38% of the patients there was no residual tumour postoperatively, in 40.8% the residual tumour was smaller than 2 cm. In 51.5% bowel resections were necessary, a stoma was unavoidable in just one case. A lymphadenectomy (pelvic, paraaortic or combined) was done in 46.6% of the patients. Postoperatively, 54.4% of the patients received a platinum-based chemotherapy, in the other patients other kinds of chemotherapy were applied. A radiation of the whole abdomen was done only in 3.9%. A median survival time for more than 60 months could be achieved in tumour-free patients due to the increased radical operations in combination with the platinum based chemotherapy. The lymphadenectomy seems to prolong the survival time of the patients. The positive nodal status is definitely unfavourable for the prognosis. By this therapeutic approach, an increased survival time with a good life quality can be achieved.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Carboplatin
KW - Chemotherapy, Adjuvant
KW - Cisplatin
KW - Combined Modality Therapy
KW - Cyclophosphamide
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Lymph Node Excision
KW - Male
KW - Middle Aged
KW - Neoplasm Staging
KW - Ovarian Neoplasms
KW - Ovariectomy
KW - Radiotherapy Dosage
KW - Survival Rate
U2 - 10.1055/s-2007-1022886
DO - 10.1055/s-2007-1022886
M3 - SCORING: Zeitschriftenaufsatz
C2 - 8514099
VL - 53
SP - 293
EP - 302
JO - GEBURTSH FRAUENHEILK
JF - GEBURTSH FRAUENHEILK
SN - 0016-5751
IS - 5
ER -